Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Eugene Myshkin"'
Autor:
Matthew J Loza, Steven Leonardo, Dawn Waterworth, Anne Stevens, Loqmane Seridi, Eugene Myshkin
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 2 (2024)
Externí odkaz:
https://doaj.org/article/90d505cbe4c2471ba08a130aae6e7a94
Autor:
Aaron Petty, Eugene Myshkin, Haina Qin, Hong Guo, Hui Miao, Gregory P Tochtrop, Jer-Tsong Hsieh, Phillip Page, Lili Liu, Daniel J Lindner, Chayan Acharya, Alexander D MacKerell, Eckhard Ficker, Jianxing Song, Bingcheng Wang
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42120 (2012)
During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressi
Externí odkaz:
https://doaj.org/article/d179e54248b847f4955532d762afd815
Autor:
Haojia Wu, Romer Gonzalez Villalobos, Xiang Yao, Dermot Reilly, Tao Chen, Matthew Rankin, Eugene Myshkin, Matthew D. Breyer, Benjamin D. Humphreys
Publikováno v:
Cell Metab
Diabetic kidney disease (DKD) occurs in ∼40% of patients with diabetes and causes kidney failure, cardiovascular disease, and premature death. We analyzed the response of a murine DKD model to five treatment regimens using single-cell RNA sequencin
Autor:
Tatiana Khasanova, Alexey Guryanov, Eugene Myshkin, Richard J. Brennan, Tatiana Sitnik, Yuri Nikolsky, Svetlana Bureeva, Elena Litvinova, Tatiana Serebriyskaya, Tatiana Nikolskaya
Publikováno v:
Chemical Biology & Drug Design. 80:406-416
The ability to accurately predict the toxicity of drug candidates from their chemical structure is critical for guiding experimental drug discovery toward safer medicines. Under the guidance of the MetaTox consortium (Thomson Reuters, CA, USA), which
Autor:
Hong Guo, Juha P. Himanen, Kanagalaghatta R. Rajashankar, Yehuda Goldgur, Hui Miao, Dimitar B. Nikolov, Eugene Myshkin, Bingcheng Wang, My Nguyen, Matthias Buck
Publikováno v:
EMBO reports. 10:722-728
Ephrin (Eph) receptor tyrosine kinases fall into two subclasses (A and B) according to preferences for their ephrin ligands. All published structural studies of Eph receptor/ephrin complexes involve B-class receptors. Here, we present the crystal str
Autor:
Evgeny O. Danilov, Anton B. Guliaev, Hewa M. Anula, Eugene Myshkin, George S. Bullerjahn, Charles R. Luman, Michael A. J. Rodgers, Felix N. Castellano
Publikováno v:
The Journal of Physical Chemistry A. 110:2545-2559
The spectroscopic properties of the self-associated complexes formed between the anionic surface docking site of spinach plastocyanin and the cationic metalloporphyrins, in which the tyrosine 83 (Y83) moiety is placed just below the docking site, tet
Autor:
Marina V. Backer, Brian T. Jehning, Joseph M. Backer, Timur I. Gaynutdinov, Eugene Myshkin, Vimal Patel
Publikováno v:
Bioconjugate Chemistry. 15:1021-1029
High-affinity interactions of two fragments of human RNase I (1-15-aa Hu-tag and 21-125-aa HuS adapter protein) can be used for assembly of targeting drug delivery complexes. In this approach, a targeting protein is expressed as a fusion protein with
Publikováno v:
Protein Engineering Design and Selection. 16:771-775
Assembled modular complexes for targeted drug delivery can be based on strong non-covalent interactions between a cargo module containing an adapter protein and a docking tag fused to a targeting protein. We have recently constructed a completely hum
Autor:
Bingcheng Wang, Eugene Myshkin
Publikováno v:
Journal of Chemical Information and Computer Sciences. 43:1004-1010
Eph receptor tyrosine kinases are divided on two subfamilies based on their affinity for ephrin ligands and play a crucial role in the intercellular processes such as angiogenesis, neurogenesis, and carcinogenesis. As such, Eph kinases represent pote
Autor:
Eugene, Myshkin, Richard, Brennan, Tatiana, Khasanova, Tatiana, Sitnik, Tatiana, Serebriyskaya, Elena, Litvinova, Alexey, Guryanov, Yuri, Nikolsky, Tatiana, Nikolskaya, Svetlana, Bureeva
Publikováno v:
Chemical biologydrug design. 80(3)
The ability to accurately predict the toxicity of drug candidates from their chemical structure is critical for guiding experimental drug discovery toward safer medicines. Under the guidance of the MetaTox consortium (Thomson Reuters, CA, USA), which